Barclays analyst Peter Lawson views the Financial Times’ report that GSK (GSK) has interest in acquiring companies with a market capitalization in the $1.0B-$2.5B range, are under-the-radar, and with drugs that can be approved in the medium term as positive for the biotech tape. Renewed acquisition activity would help improve biotech sentiment and the overall index performance, Lawson tells investors in a research note. He sees a positive read-through to oncology companies with late-stage assets, namely Arvinas (ARVN), Replimune Group (REPL), Kura Oncology (KURA), Iovance Biotherapeutics (IOVA), Syndax (SNDX), SpringsWorks Therapeutics (SWTX), Bicycle Therapeutics (BCYC) and Karyopharm (KPTI).
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARVN:
- Arvinas appoints Everett Cunningham to board of directors
- Arvinas Announces Changes to its Board of Directors
- Arvinas price target lowered to $72 from $88 at Citi
- Analysts Say These 2 ‘Strong Buy’ Stocks Are Their Top Picks for 2023
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)